As part of our series focussing on available medicines in Australia, we have added a product review of the use of finerenone to delay progressive decline of kidney function to reduce the risk of cardiovascular mortality and morbidity in adults with T2DM-associated CKD.
This review discusses pharmacological and clinical characteristics of finerenone, indications and dosage, contraindications and a series of clinical studies featuring finerenone use. It also provides commentary from Associate Professor Bobby Chacko, Director of Renal Services and Senior staff specialist at the John Hunter Hospital, Newcastle.
Please login below to download this issue (PDF)